The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses

• Michele Tameris ,

  * E-mail: Michele.tameris@uct.ac.za

  Affiliation South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa

  ⨯
• Hennie Geldenhuys,

  Affiliation South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa

  ⨯
• Angelique KanyKany Luabeya,

  Affiliation South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa

  ⨯
• Erica Smit,

  Affiliation South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa

  ⨯
• Jane E. Hughes,

  Affiliation South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa

  ⨯
• Samantha Vermaak,

  Affiliation Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

  ⨯
• Willem A. Hanekom,

  Affiliation South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa

  ⨯
• Mark Hatherill,

  Affiliation South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa

  ⨯
• Hassan Mahomed,

  Affiliation South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa

  ⨯
• Helen McShane ,

  Contributed equally to this work with: Helen McShane, Thomas J. Scriba

  Affiliation Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

  ⨯
• Thomas J. Scriba

  Contributed equally to this work with: Helen McShane, Thomas J. Scriba

  Affiliation South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa

  ⨯